Literature DB >> 28473905

Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.

Nathan D Gay1, Craig Y Okada2, Andy I Chen2, Emma C Scott2.   

Abstract

Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.

Entities:  

Keywords:  Hodgkin lymphoma; checkpoint inhibitor; immunotherapy; nivolumab; programmed cell death 1; programmed cell death-ligand 1; programmed cell death-ligand 2

Year:  2017        PMID： 28473905      PMCID： PMC5407507          DOI： 10.1177/2040620717695723

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  29 in total

1.  Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.

Authors:  Semra Paydas; Emine Bağır; Gulsah Seydaoglu; Vehbi Ercolak; Melek Ergin
Journal:  Ann Hematol       Date:  2015-05-26       Impact factor: 3.673

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

4.  Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2016-02

5.  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.

Authors:  Ajay K Gopal; Oliver W Press; Andrei R Shustov; Stephen H Petersdorf; Ted A Gooley; Jasmine T Daniels; Mitchell A Garrison; George F Gjerset; Matthew Lonergan; Anne E Murphy; Julie C Smith; John M Pagel
Journal:  Leuk Lymphoma       Date:  2010-08

6.  Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Authors:  Yu-Tzu Tai; Xian-Feng Li; Laurence Catley; Rory Coffey; Iris Breitkreutz; Jooeun Bae; Weihua Song; Klaus Podar; Teru Hideshima; Dharminder Chauhan; Robert Schlossman; Paul Richardson; Steven P Treon; Iqbal S Grewal; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.

Authors:  Andreas Josting; Lucia Nogová; Jeremy Franklin; Jan-Peter Glossmann; Hans Theodor Eich; Markus Sieber; Thomas Schober; Heinz-Dietrich Boettcher; Ulrich Schulz; Rolf-Peter Müller; Volker Diehl; Andreas Engert
Journal:  J Clin Oncol       Date:  2005-01-04       Impact factor: 44.544

8.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Authors:  Anas Younes; Anna Sureda; Dina Ben-Yehuda; Pier Luigi Zinzani; Tee-Chuan Ong; H Miles Prince; Simon J Harrison; Mark Kirschbaum; Patrick Johnston; Jennifer Gallagher; Christophe Le Corre; Angela Shen; Andreas Engert
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

9.  Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Peter Martin; Nicole Tsai; Young Kim; Bihong T Chen; Leslie Popplewell; Tanya Siddiqi; Sandra H Thomas; Michelle Mott; Firoozeh Sahebi; Saro Armenian; John Leonard; Auayporn Nademanee; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-26       Impact factor: 5.742

10.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245
View more
  2 in total

1.  Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.

Authors:  Peter Hollander; Rose-Marie Amini; Beatrice Ginman; Daniel Molin; Gunilla Enblad; Ingrid Glimelius
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

2.  Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.

Authors:  Kristiina Karihtala; Suvi-Katri Leivonen; Oscar Brück; Marja-Liisa Karjalainen-Lindsberg; Satu Mustjoki; Teijo Pellinen; Sirpa Leppä
Journal:  Cancers (Basel)       Date:  2020-04-04       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.